Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses

Psychosis

Volumn 2, Issue 1, 2010, Pages 50-69

  Weinmann, Stefan ^a   Aderhold, Volkmar ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Antipsychotics; Mortality; Neurodegeneration; Psychosis; Schizophrenia

Indexed keywords

EID: 79953109704     PISSN: 17522439     EISSN: 17522447     Source Type: Journal    
DOI: 10.1080/17522430903501999     Document Type: Article

References (100)

1. Alanen, Y., de Chavez, M., Silver, A., & Martindale, B. (2009). Psychotherapeutic approaches to schizophrenic psychoses. London: Routledge.
2. Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K., & Sidhom, T. (2004). Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry, 65, 464–470.
3. Barbui, C., Nosè, M., Mazzi, M.A., Thornicroft, G., Schene, A., Becker, T., et al. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21, 355–362.
4. Barnes, T.R., & McPhillips, M.A. (1995). How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. International Clinical Psychopharmacology, 10(Suppl. 3), 115–121.
5. Bentall, R. (2009). Doctoring the mind: Why psychiatric treatments fail. London: Penguin.
6. Bola, J.R. (2006). Medication-free research in early episode schizophrenia: Evidence of longterm harm? Schizophrenia Bulletin, 32, 288–296.
7. Bola, J.R., Lehtinen, K., Cullberg, J., & Ciompi, L. (2009). Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: A review of the literature. Psychosis: Psychological, Social and Integrative Approaches, 1, 4–18.
8. Bonelli, R.M., Hofmann, P., Aschoff, A., Niederwieser, G., Heuberger, C., Jirikowski, G., et al. (2005). The influence of psychotropic drugs on cerebral cell death: Female neurovulnerability to antipsychotics. International Clinical Psychopharmacology, 20, 145–149.
9. Bralet, M.C., Yon, V., Loas, G., & Noisette, C. (2000). Cause of mortality in schizophrenic patients: Prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale, 26, 32–41.
10. Brown, S., Birtwistle, J., Roe, L., & Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697–701.
11. Cahn, W., Hulshoff-Pol, H.E., Lems, E.B., van Haren, N.E., Schnack, H.G., van der Linden, J.A., et al. (2002). Brain volume changes in first-episode schizophrenia: A 1-year follow-up study. Archives of General Psychiatry, 59(11), 1002–1010.
12. Centers for Disease Control and Prevention (2003). Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000. Morbidity and Mortaloty Weekly Report, 52, 833–837.
13. Citrome, L. (2007). The effectiveness criterion: Balancing efficacy against the risks of weight gain. Journal of Clinical Psychiatry, 65(Suppl. 12), 12–17.
14. Citrome, L., Jaffe, A., Levine, J., Allingham, B., & Robinson, J. (2004). Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services, 55, 1006–1013.
15. Correll, C.U., Frederickson, A.M., Kane, J.M., & Manu, P. (2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry, 67, 575–583.
16. Correll, C.U., Frederickson, A.M., Kane, J.M., & Manu, P. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research, 89, 91–100.
17. Correll, C.U., & Schenk, E.M. (2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 21, 151–156.
18. Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., & Malhotra, A.K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association, 28, 1765–1773.
19. Daumit, G.L., Goff, D.C., Meyer, J.M., Davis, V.G., Nasrallah, H.A., McEvoy, J.P., et al., Antipsychotic effects on estimated 10-year coronary heart disease risk in the CaTIE schizophrenia study. Schizophrenia Research, 105, 175–187.
20. Dazzan, P., Morgan, K.D., Orr, K., Hutchinson, G., Chitnis, X., Suckling, J., et al. (2005). Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: The AESOP study. Neuropsychopharmacology, 30, 765–774.
21. Dean, C.E. (2006). Antipsychotic-associated neuronal changes in the brain: Toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Progress in Neuropsychopharmacology & Biological Psychiatry, 30, 174–189.
22. Dean, C.E., & Thuras, P.D. (2009). Mortality and tardive dyskinesia: Long-term study using the US National Death Index. British Journal of Psychiatry, 194, 360–364.
23. de Leon, J. (2008). Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. Journal of Clinical Psychopharmacology, 28, 125–131.
24. deHaan, L., Booij, J., Lavalaye, J., van, A.T., & Linszen, D. (2006). Occup ancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berlin), 183, 500–505.
25. Dorph-Petersen, K.A., Pierri, J.N., Perel, J.M., Sun, Z., Sampson, A.R., & Lewis, D.A. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 30, 1649–1661.
26. Enger, C., Weatherby, L., Reynolds, R.F., Glasser, D.B., & Walker, A.M. (2004). Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous and Mental Disease, 192, 19–27.
27. Ford, E.S., Giles, W.H., & Dietz, W.H. (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Journal of the American Medical Association, 287, 356–359.
28. Galili-Mosberg, R., Gil-Ad, I., Weizman, A., Melamed, E., & Often, D. (2000), Haloperidol- induced neurotoxicity - Possible implications for tardive dyskinesia. Journal of Neural Transmission, 107, 479–490.
29. Garver, D.L., Holcomb, J.A., & Christensen, J.D. (2005). Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biological Psychiatry, 58, 62–66.
30. Garver, D.L., Nair, T.R., Christensen, J.D., Holcomb, J.A., & Kingsbury, S.J. (2000). Brain and ventricle instability during psychotic episodes of the schizophrenias. Schizophrenia Research, 44, 11–23.
31. Gilbert, P.L., Harris, M.J., McAdams, L.A., & Jeste, D.V. (1995). Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry, 52, 173–188.
32. Glassman, A.H. (2005). Schizophrenia, antipsychotic drugs, and cardiovascular disease. Journal of Clinical Psychiatry, 66(Suppl. 6), 5–10.
33. Glassman, A.H., & Bigger, J.T., Jr. (2001). Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158, 1774–1782.
34. Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., Lenfant, C., National Heart, Lung, and Blood Institute, American Heart Association (2004). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433–438.
35. Gur, R.E., Maany, V., Mozley, P.D., Swanson, C., Bilker, W., & Gur, R.C. (1998). Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. American Journal of Psychiatry, 155, 1711–1717.
36. Haddad, P.M., & Anderson, I.M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62, 1649–1671.
37. Hagg, S., Bate, A., Stahl, M., & Spigset, O. (2008). Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Safety, 31, 685–694.
38. Halim, N.D., Weickert, C.S., McClintock, B.W., Weinberger, D.R., & Lipska, B.K. (2004). Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology, 29(6), 1063–1069.
39. Haukka, J., Tiihonen, J., Harkanen, T., & Lonnqvist, J. (2008). Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety, 17, 686–696.
40. Henderson, D.C., Nguyen, D.D., Copeland, P.M., Hayden, D.L., Borba, C.P., Louie, P.M., et al., Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry, 66, 1116–1121.
41. Hennessy, S., Bilker, W.B., Knauss, J.S., Margolis, D.J., Kimmel, S.E., Reynolds, R.F., et al., Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. British Medical Journal, 325, 1070.
42. Ho, B.C., Andreasen, N.C., Nopoulos, P., Arndt, S., Magnotta, V., & Flaum, M. (2003). Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry, 60(6), 585–594.
43. Jeste, D.B., & Wyatt, R.J. (1981). Changing epidemiology of tardive dyskinesia: An overview. American Journal of Psychiatry, 138, 297–309.
44. Jones, P.B., Barnes, T.R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., et al. (2006). Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63, 1079–1087.
45. Joseph, K.S., Blais, L., Ernst, P., & Suissa, S. (1996). Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. British Medical Journal, 312, 79–82.
46. Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122–127.
47. Kapur, S., Agid, O., Mizrahi, R., & Li, M. (2006). How antipsychotics work - From receptors to reality. NeuroRx, 3, 10–21.
48. Keshavan, M.S., Bagwell, W.W., Haas, G.L., Sweeney, J.A., Schooler, N. R., & Pettegrew, J.W., (1994). Changes in caudate volume with neuroleptic treatment. Lancet, 344(8934), 1434.
49. Konopaske, G.T., Dorph-Petersen, K.-A., Sweet, R.A., Pierri, J.N., Zhang, W., Sampson, A.R., et al. (2008). Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry, 63, 759–765.
50. Lacro, J., Dunn, L., & Dolder, C. (2002). Prevalence of risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review. Journal of Cognitive Psychotherapy, 17, 375–383.
51. Leslie, D.L., Mohamed, S., & Rosenheck, R.A. (2009). Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatric Services, 60, 1175–1181.
52. Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D., et al. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry, 49, 487–499.
53. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., et al. (2005a). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
54. Lieberman, J.A., Tollefson, G.D., Charles, C., Zipursky, R., Sharma, T., Kahn, R.S., et al. (2005b). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361–370.
55. Loas, G., Azi, A., Noisette, C., & Yon, V. (2008). [Mortality among chronic schizophrenic patients: A prospective 14-year follow-up study of 150 schizophrenic patients.] [In French.] Encephale, 34, 54–60.
56. Madsen, A.L., Karle, A., Rubin, P., Cortsen, M., Andersen, H.S., & Hemmingsen, R. (1999). Progressive atrophy of the frontal lobes in first-episode schizophrenia: Interaction with clinical course and neuroleptic treatment. Acta Psychiatrica Scandinavica, 100, 367–374.
57. Madsen, A.L., Keidling, N., Karle, A., Esbjerg, S., & Hemmingsen, R. (1998). Neuroleptics in progressive structural brain abnormalities in psychiatric illness. Lancet, 352(9130), 784–785.
58. Manderscheid, R.W. (2009). Premature death among state mental health agency consumers: Assessing progress in addressing a quiet tragedy. International Journal of Public Health, 54, 1–2.
59. McClure, R.K., Phillips, I., Jazayerli, R., Barnett, A., Coppola, R., & Weinberger, D.R., Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Research, 148, 121–132.
60. McEvoy, J.P., Meyer, J.M., Goff, D.C., Nasrallah, H.A., Davis, S.M., Sullivan, L., et al., Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19–32.
61. Mehta, D., Mallya, A., & Volavka, J. (1978). Mortality of patients with tardive dyskinesia. American Journal of Psychiatry, 135, 371–372.
62. Meyer, J.M. (2007). Stategies for the long-term treatment of schiziophrenia: Real-world lessons from the CATIE Trial. Journal of Clinical Psychiatry, 68(Suppl. 1), 28–33.
63. Meyer, J.M., Nasrallah, H.A., McEvoy, J.P., Goff, D.C., Davis, S.M., Chakos, M., et al., The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 80, 9–18.
64. Miller, d.D., Caroff, S.N., Davis, S.M., Rosenheck, R.A., McEvoy, J.P., Saltz, B.L., et al., Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journl of Psychiatry, 193, 279–288.
65. Mitchell, A.J., & Malone, D. (2006). Physical health and schizophrenia. Current Opinion in Psychiatry, 19, 432–437.
66. Modestin, J., Vogt-Wehrli, M., Stephan, P.L. & Agarwalla, P. (2009). Relationship between neuroleptic extrapyramidal syndromes and patients’ all-cause mortality. Pharmacopsychiatry, 42, 57–60.
67. Molina, V., Reig, S., Sanz, J., Palomo, T., Benito, C., Sanchez, J., et al. (2005). Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia Research, 80, 61–71.
68. Montout, C., Casadebaig, F., Lagnaoui, R., Verdoux, H., Philippe, A., Begaud, B., et al., Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 57, 147–156.
69. Morgan, M.G., Scully, P.J., Youssef, H.A., Kinsella, A., Owens, J.M., & Waddington, J.L., Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: A 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Research, 117, 127–135.
70. Nasrallah, H.A. (2008). Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Molecular Psychiatry, 13, 27–35.
71. National Institute for Health and Clinical Excellence (NICE) (2009). Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). London: NICE.
72. Navari, S., & Dazzan, P. (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine, 39, 1763–1777.
73. Noh, J.S., Kang, H.J., Kim, E.Y., Sohn, S., Chung, Y.K., Kim, S.U., et al. (2000). Haloperidol-induced neuronal apoptosis: Role of p38 and c-Jun-NH(2)-terminal protein kinase. Journal of Neurochemistry, 75, 2327–2334.
74. Osborn, D.P., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M.B. (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Archives of General Psychiatry, 64, 242–249.
75. Osborn, D.P., Nazareth, I., & King, M.B. (2007). Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness: A cross sectional comparative study in primary care. Social Psychiatry and Psychiatric Epidemiology, 42, 787–793.
76. Pandurangi, A.K. & Dalkilic, A. (2008). Polypharmacy with second-generation antipsychotics: A review of evidence. Journal of Psychiatric Practice, 14, 345–367.
77. Pantelis, C., Yücel, M., Wood, S.J., Velakoulis, D., Sun, D., Berger, G., et al. (2005). Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin, 31, 672–696.
78. Ray, W.A. (2005). Observational studies on drugs and mortality. New England Journal of Medicine, 353, 2319–2321.
79. Ray, W.A., Chung, C.P., Murray, K.T., Hall, K., & Stein, C.M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine, 360, 225–235.
80. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K., & Murray, K.T. (2001). Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 1161–1167.
81. Reist, C., Mintz, J., Albers, L.J., Jamal, M.M., Szabo, S., & Ozdemir, V. (2007). Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: An observational pharmacoepidemiology study from 1988 to 2002. Journal of Clinical Psychopharmacology, 27, 46–51.
82. Rosenheck, R.A., Leslie, D.L., Sindelar, J., Miller, E A., Lin, H., Stroup, T.S., et al. (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163, 2080–2089.
83. Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry, 64, 1123–1131.
84. Scherk, H. & Falkai, P. (2006). Effects of antipsychotics on brain structure. Current Opinion in Psychiatry, 19, 145–150.
85. Sengupta, S., Parrilla-Escobar, M.A., Klink, R., Fathalli, F., Ying, K. N., Stip, E., et al., Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophrenia Research, 102, 329–336.
86. Shenton, M.E., Dickey, C.C., Frumin, M., & McCarley, R.W. (2001). A review of MRI findings in schizophrenia. Schizophrenia Research, 49, 1–52.
87. Sicouri, S., & Antzelevitch, C. (2008). Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opinion in Drug Safety, 7, 181–194.
88. Smieskova, R., Fusar-Poli, P., Allen, P., Bendfeldt, K., Stieglitz, R.D., Drewe, J., et al., The effects of antipsychotics on the brain: What have we learnt from structural imaging of schizophrenia? - A systematic review. Current Pharmaceutical Design, 15, 2535–2549.
89. Suvisaari, J., Perala, J., Saarni, S.I., Harkanen, T., Pirkola, S., Joukamaa, M., et al. (2008). Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. European Archives of Psychiatry and Clinical Neuroscience, 258, 129–136.
90. Thompson, P.M., Bartzokis, G., Hayashi, K.M., Klunder, A.D., Lu, P.H., Edwards, N., et al., Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex, 19, 1107–1123.
91. Tiihonen, J., Walhbeck, K., Lonnqvist, J., Klaukka, T., loannidis, J.P., Volavka, J., et al., Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. British Medical Journal, 333, 224.
92. Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., et al., (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet, 374(9690), 620–627.
93. Timmer, T.J. & Fouwels, A.J. (2007). [Choking caused by antipsychotic s.] Tijdschrift for Psychiatrie, 49, 743–751.
94. von Hausswolff-Juhlin, Y., Bjartveit, M., Lindstrom, E., & Jones, P. (2009). Schizophrenia and physical health problems. Acta Psychiatrica Scandinavica Suppl, 15–21.
95. Waddington, J.L., Youssef, H.A., & Kinsella, A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.
96. Walker, A.M., Lanza, L.L., Arellano, F., & Rothman, K.J. (1997). Mortality in current and former users of clozapine. Epidemiology, 8, 671–677.
97. Wang, H.D., Dunnavant, F.D., Jarman, T., & Deutch, A.Y. (2004). Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology, 29, 1230–1238.
98. Weinberger, D.R. & McClure, R.K. (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: What is happening in the schizophrenic brain? Archives of General Psychiatry, 59, 553–558.
99. Weinmann, S., Read, J., & Aderhold, V. (2008). Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophrenia Research, 113, 1–11.
100. Weiser, M., Knobler, H., Lubin, G., Nahon, D., Kravitz, E., Caspi, A., et al. (2004). Body mass index and future schizophrenia in Israeli male adolescents. Journal of Clinical Psychiatry, 65, 1546–1549.